These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 33267874)
21. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735 [TBL] [Abstract][Full Text] [Related]
22. Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects. Shah D; Joshi M; Patel BM Fundam Clin Pharmacol; 2022 Oct; 36(5):766-776. PubMed ID: 35338518 [TBL] [Abstract][Full Text] [Related]
23. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. D'Assoro AB; Busby R; Suino K; Delva E; Almodovar-Mercado GJ; Johnson H; Folk C; Farrugia DJ; Vasile V; Stivala F; Salisbury JL Oncogene; 2004 May; 23(23):4068-75. PubMed ID: 15064746 [TBL] [Abstract][Full Text] [Related]
24. Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model. Harrison Pitner MK; Saavedra HI PLoS One; 2013; 8(6):e65971. PubMed ID: 23776583 [TBL] [Abstract][Full Text] [Related]
25. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808 [TBL] [Abstract][Full Text] [Related]
26. Tumour-associated mutant p53 drives the Warburg effect. Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z Nat Commun; 2013; 4():2935. PubMed ID: 24343302 [TBL] [Abstract][Full Text] [Related]
27. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064 [TBL] [Abstract][Full Text] [Related]
28. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011 [TBL] [Abstract][Full Text] [Related]
29. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis. Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605 [TBL] [Abstract][Full Text] [Related]
30. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412 [TBL] [Abstract][Full Text] [Related]
31. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. Fry AM; Meraldi P; Nigg EA EMBO J; 1998 Jan; 17(2):470-81. PubMed ID: 9430639 [TBL] [Abstract][Full Text] [Related]
32. Nek2 kinase in chromosome instability and cancer. Hayward DG; Fry AM Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011 [TBL] [Abstract][Full Text] [Related]
33. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664 [TBL] [Abstract][Full Text] [Related]
34. Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Oikawa T; Okuda M; Ma Z; Goorha R; Tsujimoto H; Inokuma H; Fukasawa K Mol Cell Biol; 2005 May; 25(10):4046-61. PubMed ID: 15870277 [TBL] [Abstract][Full Text] [Related]
35. Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication. Shinmura K; Bennett RA; Tarapore P; Fukasawa K Oncogene; 2007 May; 26(20):2939-44. PubMed ID: 17072342 [TBL] [Abstract][Full Text] [Related]
36. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY J Biol Chem; 2021; 296():100098. PubMed ID: 33208462 [TBL] [Abstract][Full Text] [Related]
37. Nek2-mediated GAS2L1 phosphorylation and centrosome-linker disassembly induce centrosome disjunction. Au FKC; Hau BKT; Qi RZ J Cell Biol; 2020 May; 219(5):. PubMed ID: 32289147 [TBL] [Abstract][Full Text] [Related]
38. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53. Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266 [TBL] [Abstract][Full Text] [Related]
39. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of centrosome separation after DNA damage: a role for Nek2. Fletcher L; Cerniglia GJ; Nigg EA; Yend TJ; Muschel RJ Radiat Res; 2004 Aug; 162(2):128-35. PubMed ID: 15387139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]